DDInter245 DDInter1376
Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Brompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tripelennamine
Brompheniramine {u} (Compound) resembles {v} (Compound) Captodiame
Brompheniramine {u} (Compound) resembles {v} (Compound) Pheniramine
Brompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Brompheniramine {u} (Compound) binds {v} (Gene) CYP3A4
Brompheniramine {u} (Compound) downregulates {v} (Gene) IER3
Brompheniramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Brompheniramine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Brompheniramine {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Brompheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Brompheniramine (Compound) resembles Captodiame (Compound)
Brompheniramine (Compound) resembles Pheniramine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Brompheniramine (Compound) binds CYP3A4 (Gene)
Brompheniramine (Compound) downregulates IER3 (Gene)
Brompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Brompheniramine may lead to a major life threatening interaction when taken with Potassium chloride
Brompheniramine may lead to a major life threatening interaction when taken with Zonisamide
Brompheniramine (Compound) resembles Carbinoxamine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine